XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 40.67

Change

-0.36 (-0.88)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-05 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.39 (-0.28%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

-0.20 (-0.31%)

USD 2.50B
FXH First Trust Health Care AlphaD..

-0.56 (-0.56%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

-1.45 (-1.80%)

USD 0.16B
IDNA iShares Genomics Immunology an..

-0.15 (-0.71%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-0.16 (-0.16%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

-0.37 (-1.24%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.18 (-0.66%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-0.35 (-0.60%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.55 (-2.81%)

USD 0.01B

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A
MSSS Northern Lights Fund Trus.. 9.69 % 0.00 %

-0.13 (-0.46%)

USD 0.08B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.40% 33% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.40% 33% F 34% F
Trailing 12 Months  
Capital Gain 0.20% 67% D+ 48% F
Dividend Return 1.25% 94% A 26% F
Total Return 1.44% 71% C- 39% F
Trailing 5 Years  
Capital Gain -3.24% 29% F 30% F
Dividend Return 5.94% 68% D+ 12% F
Total Return 2.71% 33% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain -3.71% 33% F 19% F
Dividend Return -2.89% 33% F 13% F
Total Return 0.81% 68% D+ 20% F
Risk Return Profile  
Volatility (Standard Deviation) 13.05% 67% D+ 70% C-
Risk Adjusted Return -22.18% 19% F 12% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.